{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T01:49:51Z","timestamp":1777081791649,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007465","name":"UiT The Arctic University of Norway","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007465","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The study\u2019s purpose was to analyze return to work and other long-term outcomes in younger patients with newly diagnosed brain metastases, treated before they reached legal retirement age, i.e. younger than 65 years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included patients who survived greater than 2 years after their first treatment, regardless of approach (systemic therapy, neurosurgical resection, whole-brain or stereotactic radiotherapy). The primary endpoint was the proportion of patients who worked 2 years after their initial treatment for brain metastases. Outcomes beyond the 2-year cut-off were also abstracted from comprehensive electronic health records, throughout the follow-up period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 455 patients who received active therapy for brain metastases, 62 (14%) survived for\u2009&gt;\u20092 years. Twenty-eight were younger than 65 years. The actuarial median survival was 81 months and the 5-year survival rate 53%. For patients alive after 5 years, the 10-year survival rate was 54%. At diagnosis, 25% of patients (7 of 28) were permanently incapacitated for work\/retired. Of the remaining 21 patients, 33% did work 2 years later. However, several of these patients went on to receive disability pension afterwards. Eventually, 19% continued working in the longer run. Younger age, absence of extracranial metastases, presence of a single brain metastasis, and Karnofsky performance status 90\u2013100 were common features of patients who worked after 2 years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Long-term survival was achieved after vastly different therapeutic approaches, regarding both upfront and sequential management. Many patients required three or more lines of brain-directed treatment. Few patients continued working in the longer run.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11060-024-04840-x","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T14:03:37Z","timestamp":1727791417000},"page":"139-154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Return to work in younger patients with brain metastases who survived for 2 years or more"],"prefix":"10.1007","volume":"171","author":[{"given":"Carsten","family":"Nieder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siv Gyda","family":"Aanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luka","family":"Stanisavljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e5rd","family":"Manns\u00e5ker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellinor Christin","family":"Haukland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"issue":"1","key":"4840_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","volume":"7","author":"EJ Lehrer","year":"2021","unstructured":"Lehrer EJ, Singh R, Wang M, Chinchilli VM, Trifiletti DM, Ost P, Siva S, Meng MB, Tchelebi L, Zaorsky NG (2021) Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis. JAMA Oncol 7(1):92\u2013106. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6146","journal-title":"JAMA Oncol"},{"key":"4840_CR2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3389\/fonc.2019.00206","volume":"9","author":"R Mazzola","year":"2019","unstructured":"Mazzola R, Corradini S, Gregucci F, Figlia V, Fiorentino A, Alongi F (2019) Role of radiosurgery\/stereotactic radiotherapy in oligometastatic disease: brain oligometastases. Front Oncol 9:206. https:\/\/doi.org\/10.3389\/fonc.2019.00206","journal-title":"Front Oncol"},{"issue":"3","key":"4840_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.rpor.2020.03.001","volume":"25","author":"C Nieder","year":"2020","unstructured":"Nieder C, Hintz M, Popp I, Bilger A, Grosu AL (2020) Long-term survival results after treatment for oligometastatic brain disease. Rep Pract Oncol Radiother 25(3):307\u2013311. https:\/\/doi.org\/10.1016\/j.rpor.2020.03.001","journal-title":"Rep Pract Oncol Radiother"},{"issue":"2","key":"4840_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/nop\/npac095","volume":"10","author":"JB Pearce","year":"2022","unstructured":"Pearce JB, Hsu FC, Lanier CM, Cramer CK, Ruiz J, Lo HW, Xing F, Smith M, Li W, Whitlow C, White JJ, Tatter SB, Laxton AW, Chan MD (2022) Five-year survivors from brain metastases treated with stereotactic radiosurgery: biology, improving treatments, or just plain luck? Neurooncol Pract 10(2):195\u2013202. https:\/\/doi.org\/10.1093\/nop\/npac095","journal-title":"Neurooncol Pract"},{"issue":"3","key":"4840_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11060-022-04036-1","volume":"158","author":"A Berger","year":"2022","unstructured":"Berger A, Bernstein K, Alzate JD, Mullen R, Silverman JS, Sulman EP, Donahue BR, Pavlick AC, Gurewitz J, Mureb M, Mehnert J, Madden K, Palermo A, Weber JS, Golfinos JG, Kondziolka D (2022) Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era? J Neurooncol 158(3):471\u2013480. https:\/\/doi.org\/10.1007\/s11060-022-04036-1","journal-title":"J Neurooncol"},{"issue":"8","key":"4840_CR6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K (2018) Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 379(8):722\u2013730. https:\/\/doi.org\/10.1056\/NEJMoa1805453","journal-title":"N Engl J Med"},{"issue":"5","key":"4840_CR7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.ijrobp.2023.12.002","volume":"118","author":"EJ Vaios","year":"2024","unstructured":"Vaios EJ, Shenker RF, Hendrickson PG, Wan Z, Niedzwiecki D, Winter SF, Shih HA, Dietrich J, Wang C, Salama AKS, Clarke JM, Allen K, Sperduto P, Mullikin T, Kirkpatrick JP, Floyd SR, Reitman ZJ (2024) Long-term intracranial outcomes with combination dual immune-checkpoint blockade and stereotactic radiosurgery in patients with melanoma and non-small cell lung cancer brain metastases. Int J Radiat Oncol Biol Phys 118(5):1507\u20131518. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.12.002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4840_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1227\/neu.0000000000002640","volume":"94","author":"E Mashiach","year":"2024","unstructured":"Mashiach E, Alzate JD, De Nigris VF, Bernstein K, Donahue BR, Schnurman Z, Gurewitz J, Rotman LE, Adams S, Meyers M, Oratz R, Novik Y, Kwa MJ, Silverman JS, Sulman EP, Golfinos JG, Kondziolka D (2024) Long-term survival from breast cancer brain metastases in the era of modern systemic therapies. Neurosurgery 94(1):154\u2013164. https:\/\/doi.org\/10.1227\/neu.0000000000002640","journal-title":"Neurosurgery"},{"key":"4840_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04749-5","author":"KL Cole","year":"2024","unstructured":"Cole KL, Earl ER, Findlay MC, Sherrod BA, Tenhoeve SA, Kunzman J, Cannon DM, Akerley W, Burt L, Seifert SB, Goldman M, Jensen RL (2024) Assessing survival in non-small cell lung cancer brain metastases after stereotactic radiosurgery: before and after the start of the targetable mutation era. J Neurooncol. https:\/\/doi.org\/10.1007\/s11060-024-04749-5","journal-title":"J Neurooncol"},{"issue":"4","key":"4840_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000529627","volume":"46","author":"C Nieder","year":"2023","unstructured":"Nieder C, Manns\u00e5ker B, Stanisavljevic L, Haukland E (2023) Patterns of care and survival in cancer patients with brain metastases receiving immune checkpoint inhibitors. Oncol Res Treat 46(4):157\u2013164. https:\/\/doi.org\/10.1159\/000529627","journal-title":"Oncol Res Treat"},{"issue":"2","key":"4840_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","volume":"9","author":"NU Lin","year":"2023","unstructured":"Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz SA, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E (2023) Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol 9(2):197\u2013205. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5610","journal-title":"JAMA Oncol"},{"issue":"8","key":"4840_CR12","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1016\/S1470-2045(23)00297-8","volume":"24","author":"MM Kim","year":"2023","unstructured":"Kim MM, Mehta MP, Smart DK, Steeg PS, Hong JA, Espey MG, Prasanna PG, Crandon L, Hodgdon C, Kozak N, Armstrong TS, Morikawa A, Willmarth N, Tanner K, Boire A, Gephart MH, Margolin KA, Hattangadi-Gluth J, Tawbi H, Trifiletti DM, Chung C, Basu-Roy U, Burns R, Oliva ICG, Aizer AA, Anders CK, Davis J, Ahluwalia MS, Chiang V, Li J, Kotecha R, Formenti SC, Ellingson BM, Gondi V, Sperduto PW, Barnholtz-Sloan JS, Rodon J, Lee EQ, Khasraw M, Yeboa DN, Brastianos PK, Galanis E, Coleman CN, Ahmed MM (2023) National Cancer Institute collaborative workshop on shaping the landscape of brain metastases research: challenges and recommended priorities. Lancet Oncol 24(8):e344\u2013e354. https:\/\/doi.org\/10.1016\/S1470-2045(23)00297-8","journal-title":"Lancet Oncol"},{"issue":"5","key":"4840_CR13","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ijrobp.2007.03.048","volume":"68","author":"H Aoyama","year":"2007","unstructured":"Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo M, Hirota S, Shioura H, Inomata T, Kunieda E, Hayakawa K, Nakagawa K, Kobashi G, Shirato H (2007) Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 68(5):1388\u20131395. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.03.048","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"4840_CR14","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","volume":"10","author":"EL Chang","year":"2009","unstructured":"Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037\u20131044. https:\/\/doi.org\/10.1016\/S1470-2045(09)70263-3","journal-title":"Lancet Oncol"},{"issue":"2","key":"4840_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.semradonc.2023.01.005","volume":"33","author":"C Nieder","year":"2023","unstructured":"Nieder C, Andratschke NH, Grosu AL (2023) Brain metastases: Is there still a role for whole-brain radiation therapy? Semin Radiat Oncol 33(2):129\u2013138. https:\/\/doi.org\/10.1016\/j.semradonc.2023.01.005","journal-title":"Semin Radiat Oncol"},{"issue":"7","key":"4840_CR16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/jama.2009.187","volume":"301","author":"AG de Boer","year":"2009","unstructured":"de Boer AG, Taskila T, Ojaj\u00e4rvi A, van Dijk FJ, Verbeek JH (2009) Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA 301(7):753\u2013762. https:\/\/doi.org\/10.1001\/jama.2009.187","journal-title":"JAMA"},{"key":"4840_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11764-008-0053-2","volume":"3","author":"A Syse","year":"2008","unstructured":"Syse A, Tretli S, Kravdal \u00d8 (2008) Cancer\u2019s impact on employment and earnings\u2014a population-based study from Norway. J Cancer Surviv 3:149\u2013158. https:\/\/doi.org\/10.1007\/s11764-008-0053-2","journal-title":"J Cancer Surviv"},{"issue":"5","key":"4840_CR18","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s11764-021-01097-5","volume":"16","author":"CJ Tan","year":"2022","unstructured":"Tan CJ, Yip SYC, Chan RJ, Chew L, Chan A (2022) Investigating how cancer-related symptoms influence work outcomes among cancer survivors: a systematic review. J Cancer Surviv 16(5):1065\u20131078. https:\/\/doi.org\/10.1007\/s11764-021-01097-5","journal-title":"J Cancer Surviv"},{"issue":"7","key":"4840_CR19","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.21873\/anticanres.17134","volume":"44","author":"C Nieder","year":"2024","unstructured":"Nieder C, Haukland EC, Manns\u00e5ker B (2024) Return to work after breast cancer treatment: an electronic health record-based study in North Norway. Anticancer Res 44(7):3193\u20133198. https:\/\/doi.org\/10.21873\/anticanres.17134","journal-title":"Anticancer Res"},{"issue":"3","key":"4840_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11060-022-04183-5","volume":"160","author":"CM Lanier","year":"2022","unstructured":"Lanier CM, Pearce J, Isom S, Xing F, Lo HW, Whitlow CT, Ruiz J, White JJ, Laxton AW, Tatter SB, Cramer CK, Chan MD (2022) Long term survivors of stereotactic radiosurgery for brain metastases: do distant brain failures reach a plateau and what factors are associated with a brain metastasis velocity of zero? J Neurooncol 160(3):643\u2013648. https:\/\/doi.org\/10.1007\/s11060-022-04183-5","journal-title":"J Neurooncol"},{"issue":"9","key":"4840_CR21","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/neuonc\/now290","volume":"19","author":"AS Berghoff","year":"2017","unstructured":"Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Bartsch R, Zielinski CC, Weller M, Preusser M (2017) Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score. Neuro Oncol 19(9):1255\u20131262. https:\/\/doi.org\/10.1093\/neuonc\/now290","journal-title":"Neuro Oncol"},{"issue":"5","key":"4840_CR22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.5603\/RPOR.a2021.0096","volume":"26","author":"C Nieder","year":"2021","unstructured":"Nieder C, Dalhaug A, Haukland E (2021) The LabBM score is an excellent survival prediction tool in patients undergoing palliative radiotherapy. Rep Pract Oncol Radiother 26(5):740\u2013746. https:\/\/doi.org\/10.5603\/RPOR.a2021.0096","journal-title":"Rep Pract Oncol Radiother"},{"issue":"4","key":"4840_CR23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3109\/0284186X.2011.640710","volume":"51","author":"A Syse","year":"2012","unstructured":"Syse A, T\u00f8nnessen M (2012) Cancer\u2019s unequal impact on incomes in Norway. Acta Oncol 51(4):480\u2013489. https:\/\/doi.org\/10.3109\/0284186X.2011.640710","journal-title":"Acta Oncol"},{"key":"4840_CR24","doi-asserted-by":"publisher","first-page":"26686","DOI":"10.3402\/ijch.v74.26686","volume":"74","author":"H Egestad","year":"2015","unstructured":"Egestad H, Nieder C (2015) Undesirable financial effects of head and neck cancer radiotherapy during the initial treatment period. Int J Circumpolar Health 74:26686. https:\/\/doi.org\/10.3402\/ijch.v74.26686","journal-title":"Int J Circumpolar Health"},{"issue":"4","key":"4840_CR25","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1016\/S1470-2045(23)00636-8","volume":"25","author":"M Schlander","year":"2024","unstructured":"Schlander M, van Harten W, Ret\u00e8l VP, Pham PD, Vancoppenolle JM, Ubels J, L\u00f3pez OS, Quirland C, Maza F, Aas E, Crusius B, Escobedo A, Franzen N, Fuentes-Cid J, Hernandez D, Hernandez-Villafuerte K, Kirac I, Paty A, Philip T, Smeland S, Sullivan R, Vanni E, Varga S, Vermeulin T, Eckford RD (2024) The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions. Lancet Oncol 25(4):e152\u2013e163. https:\/\/doi.org\/10.1016\/S1470-2045(23)00636-8","journal-title":"Lancet Oncol"},{"issue":"3","key":"4840_CR26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11060-023-04384-6","volume":"163","author":"S Leskinen","year":"2023","unstructured":"Leskinen S, Shah HA, Yaffe B, Schneider SJ, Ben-Shalom N, Boockvar JA, D\u2019Amico RS, Wernicke AG (2023) Hippocampal avoidance in whole brain radiotherapy and prophylactic cranial irradiation: a systematic review and meta-analysis. J Neurooncol 163(3):515\u2013527. https:\/\/doi.org\/10.1007\/s11060-023-04384-6","journal-title":"J Neurooncol"},{"issue":"3\u20135","key":"4840_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.seminoncol.2023.09.004","volume":"50","author":"HP Surendran","year":"2023","unstructured":"Surendran HP, Sah SK, Louis DM, Kalavagunta S, Poornachary NM, Joy SC, Dutta D (2023) Efficacy of memantine in preventing neurocognitive dysfunction induced by radiation therapy in patients with brain metastases: a systematic review of clinical trials. Semin Oncol 50(3\u20135):113\u2013122. https:\/\/doi.org\/10.1053\/j.seminoncol.2023.09.004","journal-title":"Semin Oncol"},{"issue":"2","key":"4840_CR28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s11764-019-00828-z","volume":"14","author":"P Butow","year":"2020","unstructured":"Butow P, Laidsaar-Powell R, Konings S, Lim CYS, Koczwara B (2020) Return to work after a cancer diagnosis: a meta-review of reviews and a meta-synthesis of recent qualitative studies. J Cancer Surviv 14(2):114\u2013134. https:\/\/doi.org\/10.1007\/s11764-019-00828-z","journal-title":"J Cancer Surviv"},{"issue":"2","key":"4840_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11764-022-01202-2","volume":"18","author":"SH B\u00f8hn","year":"2024","unstructured":"B\u00f8hn SH, Vandraas KF, Kiserud CE, Dahl AA, Thorsen L, Ewertz M, Lie HC, Falk R, Reinertsen KV (2024) Work status changes and associated factors in a nationwide sample of Norwegian long-term breast cancer survivors. J Cancer Surviv 18(2):375\u2013384. https:\/\/doi.org\/10.1007\/s11764-022-01202-2","journal-title":"J Cancer Surviv"},{"issue":"10","key":"4840_CR30","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1007\/s00066-022-01950-1","volume":"198","author":"M Salzmann","year":"2022","unstructured":"Salzmann M, Hess K, Lang K, Enk AH, Jordan B, Hassel JC (2022) Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy. Strahlenther Onkol 198(10):884\u2013891. https:\/\/doi.org\/10.1007\/s00066-022-01950-1","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"4840_CR31","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1007\/s00520-022-06838-5","volume":"30","author":"A Sekely","year":"2022","unstructured":"Sekely A, Zakzanis KK, Mabbott D, Tsang DS, Kongkham P, Zadeh G, Edelstein K (2022) Long-term neurocognitive, psychological, and return to work outcomes in meningioma patients. Support Care Cancer 30(5):3893\u20133902. https:\/\/doi.org\/10.1007\/s00520-022-06838-5","journal-title":"Support Care Cancer"},{"issue":"6","key":"4840_CR32","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.3171\/2018.3.FOCUS1819","volume":"44","author":"D Starnoni","year":"2018","unstructured":"Starnoni D, Berthiller J, Idriceanu TM, Meyronet D, d\u2019Hombres A, Ducray F, Guyotat J (2018) Returning to work after multimodal treatment in glioblastoma patients. Neurosurg Focus 44(6):E17. https:\/\/doi.org\/10.3171\/2018.3.FOCUS1819","journal-title":"Neurosurg Focus"},{"issue":"9","key":"4840_CR33","doi-asserted-by":"publisher","first-page":"10840","DOI":"10.1002\/cam4.5752","volume":"12","author":"A Johnsson","year":"2023","unstructured":"Johnsson A, Kiani NA, Gernaat SAM, Wilking U, Shabo I, Hedayati E (2023) Planning for return to work during the first year after breast cancer metastasis: a Swedish cohort study. Cancer Med 12(9):10840\u201310850. https:\/\/doi.org\/10.1002\/cam4.5752","journal-title":"Cancer Med"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04840-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04840-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04840-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T17:03:03Z","timestamp":1735578183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04840-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["4840"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04840-x","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.G.A. has received lecture fees from Merck, BMS, Astra Zeneca and Pfizer. B.M. has received lecture fees from BMS, Astra Zeneca, Gilead, Roche, Novartis and Pfizer. L.S. has received lecture fees from Pfizer, MSD, Janssen and Ipsen. L.S. har received consulting fees from MSD. Other authors: no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This is an observational study. The REK Nord Research Ethics Committee has confirmed that no ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}